Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GlycoDesign
Toronto, Ontario, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
GlycoDesign was a Toronto-based biotechnology company specializing in glycobiology and the development of carbohydrate-based therapeutics. Founded as a spin-off from the University of Toronto, the company focused on designing small molecule inhibitors of enzymes involved in protein glycosylation to treat cancer and inflammatory diseases. Its lead clinical candidate, GD0039, was a small molecule inhibitor of alpha-mannosidase II that reached Phase 2 clinical trials for oncology. The company's platform aimed to disrupt the aberrant glycosylation patterns often found in diseased cells. In 2003, GlycoDesign was acquired by Progenics Pharmaceuticals to bolster their pipeline of carbohydrate-related therapies.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on GlycoDesign.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GlycoDesign.